YOSHlHlTO YAWATA, M.D.; ROBERT HOWE, M.D.; HARRY S. JACOB, M.D.
A plasma factor that inhibits red cell hexose monophosphate (HMP) shunt metabolism and thereby shortens red cell survival has been found to accumulate in roughly half of uremic patients. The factor is efficiently removed by frequent hemodialysis with purified water in the bath solutions. However, contaminants in tap water hemodialysis baths potentiate the red cell defect, and hemolysis may strikingly worsen in patients so dialyzed. As in patients with deficient red cell glucose-6-phosphate dehydrogenase, and thus deficient HMP shunt metabolism, explosive Heinz body hemolytic anemia may occur in affected uremic patients given oxidant drugs, such as sulfonamides, antimalarials, and the like. We urge that uremic patients be screened for red cell HMP shunt deficiency before administration of sulfonamides or other oxidant compounds and that affected patients be dialyzed only against purified water baths.
Learn more about subscription options.
Register Now for a free account.
YAWATA Y, HOWE R, JACOB HS. Abnormal Red Cell Metabolism Causing Hemolysis in Uremia: A Defect Potentiated by Tap Water Hemodialysis. Ann Intern Med. 1973;79:362–367. doi: 10.7326/0003-4819-79-3-362
Download citation file:
Published: Ann Intern Med. 1973;79(3):362-367.
Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only